切换至 "中华医学电子期刊资源库"
高级检索
中华诊断学电子杂志

中华诊断学电子杂志 ›› 2016, Vol. 04 ›› Issue (02) : 94 -97. doi: 10.3877/cma.j.issn.2095-655X.2016.02.006

所属专题： 文献；

影像学诊断研究

高分辨率CT肺小血管面积测定在肺动脉高压中的应用价值
胡燕霞1, 柳毅2,†()   
  1. 1. 332000　九江市第一人民医院呼吸内科
    2. 200233　上海交通大学附属第六人民医院呼吸内科
  • 收稿日期:2016-04-19 出版日期:2016-05-26
  • 通信作者: 柳毅

The value of high resolution computed tomographic measurement of pulmonary small vessel area in pulmonary hypertension

Yanxia Hu1, Yi Liu2,†()   

  1. 1. Department of Respiratory Medicine, Jiujiang First People's Hospital, Jiujiang 332000, China
    2. Department of Respiratory Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China
  • Received:2016-04-19 Published:2016-05-26
  • Corresponding author: Yi Liu
  • About author:
    Corresponding author: Liu Yi, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

胡燕霞, 柳毅. 高分辨率CT肺小血管面积测定在肺动脉高压中的应用价值[J]. 中华诊断学电子杂志, 2016, 04(02): 94-97.

Yanxia Hu, Yi Liu. The value of high resolution computed tomographic measurement of pulmonary small vessel area in pulmonary hypertension[J]. Chinese Journal of Diagnostics(Electronic Edition), 2016, 04(02): 94-97.

目的

探讨高分辨率CT(HRCT)测得的肺小血管截面积与肺截面积比值(%CSA)在评估慢性阻塞性肺疾病(COPD)合并肺动脉高压(PH)中的应用价值。

方法

选择行HRCT胸部平扫的COPD合并PH 20例患者及20名正常对照组资料。所有检查中均行肺功能检查(PFT)，测得第1秒用力呼气容积实测值与预计值百分比(FEV1%)和FEV1与用力肺活量之比(FEV1/FVC)。测得基于HRCT的%CSA(肺小血管截面积<5 mm2和5～10 mm2分别为%CSA<5和%CSA5～10)数据。应用独立样本t检验比较COPD合并PH组与对照组间差异，采用Spearman相关分析COPD合并PH组%CSA与PFT指标之间的相关性。

结果

COPD合并PH组和对照组的%CSA<5分别为(1.04±0.20)%、(0.82±0.14)%，差异有统计学意义(t＝4.07，P<0.01)。上述两组的%CSA5～10分别为(0.53±0.13)%、(0.33±0.08)%，差异有统计学意义(t＝5.41，P<0.01)。COPD合并PH组的FEV1%和FEV1/FVC分别为(32.40±11.31)%、(44.10±18.30)%。COPD合并PH组的%CSA<5与FEV1%和FEV1/FVC无相关性(r值分别为－0.136和－0.149，均P>0.05)。COPD合并PH组的%CSA5～10与FEV1%和FEV1/FVC无相关性(r值分别为－0.084和－0.072，均P>0.05)。

结论

COPD合并PH患者的%CSA<5 mm2和%CSA5～10 mm2较正常升高，可作为一种反映COPD合并PH严重程度的指标。

关键词: 肺疾病，慢性阻塞性, 体层摄影术，X线计算机, 高血压，肺性
Objective

To investigate the role of the percentage of the total cross-sectional area of small pulmonary vessels for the lung area (%CSA) from high resolution computed tomography(HRCT)in chronic obstructive pulmonary disease (COPD) combined pulmonary hypertension(PH).

Methods

Twenty COPD combined PH patients and 20 normal subjects underwent chest HRCT scans and all data were analyzed retrospectively.COPD combined PH patients underwent pulmonary function tests (PFT), including forced expiratory volume in one second (FEV1%) and FEV1/forced vital capacity (FEV1/FVC), respectively.The %CSA less than 5 mm2 and 5~10 mm2 for the lung area (%CSA<5 and %CSA5~10) of small pulmonary vessels were measured with HRCT.Comparison of %CSA<5 and %CSA5~10 between the COPD combined PH and control groups were performed using t test.The correlation between % CSA and PFT was evaluated by the Spearman rank correlation test.

Results

%CSA<5 of COPD combined PH patients and control group were (1.04±0.20)%、(0.82±0.14)%, respectively, the difference was statistically significant.%CSA5-10 of the two groups were (0.53±0.13)%、(0.33±0.08)% the difference between the two groups was significant. (t=5.41, P<0.01). FEV1% and FEV1/FVC in COPD patients were(32.40±11.31)% and (44.10±18.30)%.%CSA<5 in COPD patients were not correlated negatively with both FEV1% and FEV1/FVC (r=-0.136, -0.149; P>0.05). %CSA5~10 in COPD patients were not correlated negatively with both FEV1% and FEV1/FVC (r=-0.084, -0.724; P>0.05).

Conclusion

%CSA<5 and %CSA5~10 of COPD combined PH patients are higher than those of normal, they can be used as an index reflecting the severity of COPD combined PH.

Key words: Lung diseases, chronic obstructive, Tomography, X-ray computed, Hypertension, pulmonary
表1 COPD合并PH组与对照组%CSA的比较(%，±s)
组别 例数 %CSA<5 mm2 %CSA5-10 mm2
COPD合并PH组 20 1.04±0.20 0.53±0.13
对照组 20 0.82±0.14 0.33±0.08
t值 ? 4.07 5.41
P值 ? 0.00 0.00
表2 COPD合并PH组与对照组PFT的比较(%，±s)
组别 例数 FEV1实/预 FEV1/FVC
COPD合并PH组 20 32.40±11.31 44.10±18.30
对照组 20 93.55± 4.43 89.80±12.09
t值 ? 10.11 8.19
P值 ? 0.00 0.00
[7]
邹霞英,辛达临,李志斌, 等. 慢性阻塞性肺疾病与肺动脉高压自然病程的探讨[J]. 国际呼吸杂志, 2008, 28(15): 904-906.
[8]
Linguraru MG,Orandi BJ,Van Uitert RL, et al.CT and image processing non-invasive indicators of sickle cell secondary pulmonary hypertension [J]. Conf Proc IEEE Eng Med Biol Soc, 2008(2008): 859-862.
[9]
Linguraru MG,Pura JA,Van Uitert RL, et al.Segmentation and quantification of pulmonary artery for noninvasive CT assessment of sickle cell secondary pulmonary hypertension [J]. Med Phys, 2010, 37(4): 1522-1532.
[10]
Davarpanah AH,Hodnett PA,Farrelly CT, et al.MDCT bolus tracking data as an adjunct for predicting the diagnosis of pulmonary hypertension and concomitant right-heart failure [J]. AJR Am J Roentgenol, 2011, 197(5): 1064-1072.
[11]
Shoǐkhet IaN,Bednarzhevskaia TV. Computed tomography and study of external respiratory function in the diagnosis of complica tions due to chronic obstructive lung disease [J].Klin Med(Mosk), 2004, 82(7): 65-68.
[12]
高靳,余建群,白红利, 等. 慢性阻塞性肺部疾病病程与肺动脉直径变化关系的多层螺旋CT评价[J]. 实用放射学杂志, 2009；25 (3): 332-337.
[13]
Kasai H,Sugiura T,Tanabe N, et al.Electrocardiogram-gated 320-slice multidetector computed tomography for the measurement of pulmonary arterial distensibility in chronic thromboembolic pulmonary hypertension[J]. PLoS One, 2014, 9(11): e111563.
[14]
Shin S,King CS,Brown AW, et al.Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease[J]. Respir Med, 2014, 108(11): 1626-1632.
[15]
Wells JM,Dransfield MT.Pathophysiology and clinical implications of pulmonary arterial enlargement in COPD[J]. Int J Chron Obstruct Pulmon Dis, 2013(8): 509-521.
[16]
McCall RK,Ravenel JG,Nietert PJ, et al.Relationship of main pulmonary artery diameter to pulmonary arterial pressure in scleroderma patients with and without interstitial fibrosis[J]. J Comput Assist Tomogr, 2014, 38(2): 163-168.
[17]
Corson N,Armato SG 3rd,Labby ZE, et al.CT-based pulmonary artery measurements for the assessment of pulmonary hypertension[J]. Acad Radiol, 2014, 21(4): 523-530.
[18]
Matsuura Y,Kawata N,Yanagawa N, et al.Quantitative assessment of cross-sectional area of small pulmonary vessels in patients with COPD using inspiratory and expiratory MDCT[J]. Eur J Radiol, 2013, 82(10): 1804-1810.
[1]
王秋月,张明娜. 不容忽视的慢性阻塞性肺疾病合并肺动脉高压[J]. 中华结核和呼吸杂志, 2013, 36(4): 250-252.
[2]
黄宇婷,刘翱. HRCT定量测量与慢性阻塞性肺疾病表型的关系[J]. 中华肺部疾病杂志(电子版), 2015, 8(2): 105-107.
[3]
中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志, 2013, 36(4): 255-264.
[4]
Galiè N,Hoeper MM,Humbert M, et al.Guidelines for the diagnosis and treatment of pulmonary hypertension：the task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology(ESC) and the european respiratory society(ERS), endorsed by the international society of heart and lung transplantation(ISHLT)[J]. Eur Heart J, 2009, 30(20): 2493-2537.
[5]
王之悦,祝因苏,陈雪松, 等. 多层螺旋CT肺小血管与肺截面积比值评价慢性阻塞性肺疾病严重程度的作用[J]. 中华放射学杂志, 2016, 50(2): 86-90.
[6]
郭凯,殷少军. 慢性阻塞性肺疾病急性加重期相关生物标志物及其诊断意义[J/CD]. 中华诊断学电子杂志, 2015, 3(2): 133-137.
[19]
Matsuoka S,Yamashiro T,Matsushita S, et al.Relationship between quantitative CT of pulmonary small vessels and pulmonary perfusion[J]. AJR Am J Roentgenot, 2014, 202(4): 719-724.
[20]
Matsuoka S,Washko GR,Yamashiro T, et al.Pulmonary hypertension and computed tomograpahy measurement of small pulmonary vessels in severe empahysema[J]. Am J Respir Crit Care Med, 2010, 181(3): 218-225.
[1] 靳茜雅, 黄晓松, 谭诚, 蒋琴, 侯昉, 李瑶悦, 徐冰, 贾红慧, 刘文英. 产前他克莫司治疗对先天性膈疝大鼠病理模型肺血管重构的影响[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 428-436.
[2] 唐英俊, 李华娟, 王赛妮, 徐旺, 刘峰, 李羲, 郝新宝, 黄华萍. 人脐带间充质干细胞治疗COPD小鼠及机制分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 476-480.
[3] 徐丽玲, 卢玉宝, 赵彦, 任利, 李姝艺, 符娟, 康玲, 汪青松, 尤再春. COPD管理云平台的构建及临床应用[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 481-484.
[4] 李海明, 刘鸿飞, 李俊. 血清脂蛋白酶水平与COPD患者骨骼肌质量减少的关系[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 500-503.
[5] 周杉京, 诸葛金科, 王芳芳. 补肺活血胶囊对COPD患者cCor、ALD、Ang-Ⅱ的影响[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 517-519.
[6] 吴庆华, 冒勇, 闫效坤. AECOPD并发AKI的危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 529-531.
[7] 芦丹, 杨硕, 刘旭. VEGF、HMGB1、hs-CRP/Alb在AECOPD伴呼吸衰竭中的变化及预后分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 532-534.
[8] 熊锋, 娄建丽. 慢性阻塞性肺疾病急性加重期预后的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 550-553.
[9] 王庆, 张红联, 吴志勇. COPD合并多重耐药菌肺部感染预后危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 557-559.
[10] 林静, 陈芳, 刘小霞. COPD患者认知功能障碍影响因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 569-571.
[11] 张七妹, 麦宜准, 蒋浩波. 喘可治对慢性阻塞性肺疾病缓解期的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 578-580.
[12] 张林, 刘芳, 赵静, 刘勇, 周青. 远程康复在慢性阻塞性肺疾病患者肺康复中的研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 601-604.
[13] 苏国栋, 王剑桥, 刘洋, 樊祥德, 樊华, 刘惠林. 吸气肌训练对COPD运动恐动症的影响[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 421-423.
[14] 赵晓红, 修翠萍, 张瑜, 吴珂. 大康复理念在COPD稳定期肺康复治疗的临床应用[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 424-426.
[15] 刘立业, 赵德芳. 非酒精性脂肪肝患者血清细胞因子信号转导抑制因子3、肝X受体α水平与CT影像学特征的相关性[J]. 中华消化病与影像杂志(电子版), 2023, 13(04): 211-215.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号